MINK THERAPEUTICS, INC.
MINK THERAPEUTICS provides novel therapeutic products for diseases with unmet medical needs.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying MINK Therapeutics' stock with a target price of $8, suggesting growth potential.
Financial Health
Mink Therapeutics is producing solid cash flow per share, indicating good financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring INKT
MASH Biotech Stocks: What's Next After Roche Deal
Roche's acquisition of 89bio for its late-stage liver disease drug highlights a major strategic investment in the MASH treatment space. This move could increase the valuation of other biotech companies developing therapies for metabolic disorders as they become attractive M&A targets.
Published: September 18, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Cell therapy focus
Develops cell‑based immunotherapies and immune approaches; scientific progress can influence value, though clinical outcomes remain uncertain.
Early-stage potential
Small market cap can offer upside if milestones succeed, but shares are often volatile and future fundraising may dilute holders.
Regulatory pathway matters
Advancement depends on trial results and approvals across jurisdictions; commercialisation requires capital, manufacturing and partnerships.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
